1:44 PM
Jul 25, 2017
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML)

Patient sample, cell culture and mouse studies suggest inhibiting SYNCRIP could help treat AML. In bone marrow samples from patients, SYNCRIP levels were higher than in hematopoietic stem...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >